Table 2.
In vitro activity (MIC in mg/L) of study drugs against key baseline pathogens isolated from primary infection site or blood (mMITT population)
| Ceftaroline |
Vancomycin |
||||||
|---|---|---|---|---|---|---|---|
| Number of isolatesa | MIC range | MIC50b | MIC90b | MIC range | MIC50b | MIC90b | |
| Gram-positive pathogens | |||||||
| Staphylococcus aureus (total) | 217 | 0.06–1 | 0.25 | 0.5 | ≤0.25–1 | 0.5 | 1 |
| MSSA | 164 | 0.06–0.5 | 0.25 | 0.25 | ≤0.25–1 | 0.5 | 1 |
| MRSA | 54 | 0.25–1 | 0.5 | 0.5 | 0.5–1 | 0.5 | 1 |
| Streptococcus pyogenes | 25 | ≤0.008 | ≤0.008 | ≤0.008 | ≤0.25 | ≤0.25 | ≤0.25 |
| Streptococcus anginosus group | 24 | ≤0.008–0.03 | 0.03 | 0.03 | 0.5–1 | 0.5 | 1 |
| Enterococcus faecalis | 19 | 0.5–64 | 1 | 8 | 0.5–1 | 1 | 2 |
| Streptococcus agalactiae | 16 | ≤0.008–0.15 | 0.15 | 0.15 | ≤0.25–0.5 | 0.5 | 0.5 |
| Streptococcus dysgalactiae | 12 | ≤0.008–0.06 | ≤0.008 | 0.15 | ≤0.25–1 | ≤0.25 | 1 |
| Ceftaroline |
Aztreonam |
||||||
| Number of isolatesa | MIC range | MIC50b | MIC90b | MIC range | MIC50b | MIC90b | |
| Gram-negative pathogens | |||||||
| Escherichia coli | 30 | 0.015 to >32 | 0.12 | 16 | ≤0.03 to >32 | 0.12 | 4 |
| ESBL negative | 26 | ≤0.03–8 | 0.06 | 1 | ≤0.03–4 | 0.06 | 0.12 |
| Klebsiella pneumoniae | 12 | 0.06 to >32 | 0.25 | >32 | ≤0.03 to >32 | 0.06 | >32 |
| ESBL negative | 8 | 0.06–2 | NA | NA | ≤0.03–0.25 | NA | NA |
| Proteus mirabilis | 11 | 0.03 to >32 | 0.06 | 0.12 | ≤0.03–0.12 | ≤0.03 | 0.12 |
| Pseudomonas aeruginosa | 9 | 1 to >32 | NA | >32 | NA | 8 | NA |
| Klebsiella oxytoca | 8 | 0.03–0.25 | NA | NA | ≤0.03–0.25 | NA | NA |
| Morganella morganii | 7 | 0.03–0.12 | NA | NA | ≤0.03–0.12 | NA | NA |
NA, not assessed because there were <10 isolates.
aWhere there were multiple isolates for a single patient, the isolate with the highest MIC value was used. Isolates of both MSSA and MRSA from a single patient were counted only once in the total for S. aureus.
bMIC50 and MIC90 calculated for isolates where n ≥ 10.